These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23858438)

  • 1. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.
    Mahony C; Erskine L; Niven J; Greig NH; Figg WD; Vargesson N
    Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12703-8. PubMed ID: 23858438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans.
    Zeldis JB; Carter TL; Knight RD; Hui J
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):E4819. PubMed ID: 24302769
    [No Abstract]   [Full Text] [Related]  

  • 3. Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models.
    D'Amato RJ; Lentzsch S; Rogers MS
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):E4818. PubMed ID: 24302770
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos.
    Vargesson N; Mahony C; Erskine L; Niven J; Greig NH; Figg WD
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):E4820. PubMed ID: 24471177
    [No Abstract]   [Full Text] [Related]  

  • 5. In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems.
    Beedie SL; Rore HM; Barnett S; Chau CH; Luo W; Greig NH; Figg WD; Vargesson N
    Oncotarget; 2016 May; 7(22):33237-45. PubMed ID: 27120781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CPS49-induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos.
    Mahony C; McMenemy S; Rafipay AJ; Beedie SL; Fraga LR; Gütschow M; Figg WD; Erskine L; Vargesson N
    J Anat; 2018 Apr; 232(4):568-574. PubMed ID: 29023763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.
    Beedie SL; Peer CJ; Pisle S; Gardner ER; Mahony C; Barnett S; Ambrozak A; Gütschow M; Chau CH; Vargesson N; Figg WD
    Mol Cancer Ther; 2015 Oct; 14(10):2228-37. PubMed ID: 26269604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a Pregnancy Prevention Programme (PPP) with a Controlled Distribution System (CDS) for the Generic Teratogenic Phthalimides Thalidomide, Lenalidomide and Pomalidomide.
    Mueller M; Lewis DJ
    Ther Innov Regul Sci; 2021 Nov; 55(6):1155-1164. PubMed ID: 34331266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
    Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
    Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teratogenic effects of thalidomide: molecular mechanisms.
    Ito T; Ando H; Handa H
    Cell Mol Life Sci; 2011 May; 68(9):1569-79. PubMed ID: 21207098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of lenalidomide in hematological malignancies.
    Kotla V; Goel S; Nischal S; Heuck C; Vivek K; Das B; Verma A
    J Hematol Oncol; 2009 Aug; 2():36. PubMed ID: 19674465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological properties of thalidomide and its analogues.
    De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction.
    Tamalunas A; Sauckel C; Ciotkowska A; Rutz B; Wang R; Huang R; Li B; Stief CG; Gratzke C; Hennenberg M
    Life Sci; 2021 Sep; 281():119771. PubMed ID: 34186051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
    De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
    Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
    Bodera P; Stankiewicz W
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.